Advertisement

Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apo E−/− mice

      Highlights

      • A commonly used murine model of diabetes-induced atherosclerosis was investigated.
      • The effect of carnosine supplementation upon atherosclerosis was examined.
      • Blood glucose and cholesterol, glycated haemoglobin, and plaque area were unaffected.
      • There was a decrease in plasma triglycerides and increased lesion collagen content.
      • Carnosine reduced hypertriglyceridaemia and was associated with lesion remodelling.

      Abstract

      Objective

      Carnosine has been shown to modulate triglyceride and glycation levels in cell and animal systems. In this study we investigated whether prolonged supplementation with carnosine inhibits atherosclerosis and markers of lesion stability in hyperglycaemic and hyperlipidaemic mice.

      Methods

      Streptozotocin-induced diabetic apo E−/− mice were maintained for 20 weeks, post-induction of diabetes. Half of the animals received carnosine (2 g/L) in their drinking water. Diabetes was confirmed by significant increases in blood glucose and glycated haemoglobin, plasma triglyceride and total cholesterol levels, brachiocephalic artery and aortic sinus plaque area; and lower body mass.

      Results

      Prolonged carnosine supplementation resulted in a significant (∼20-fold) increase in plasma carnosine levels, and a significant (∼23%) lowering of triglyceride levels in the carnosine-supplemented groups regardless of glycaemic status. Supplementation did not affect glycaemic status, blood cholesterol levels or loss of body mass. In the diabetic mice, carnosine supplementation did not diminish measured plaque area, but reduced the area of plaque occupied by extracellular lipid (∼60%) and increased both macrophage numbers (∼70%) and plaque collagen content (∼50%). The area occupied by α-actin-positive smooth muscle cells was not significantly increased.

      Conclusions

      These data indicate that in a well-established model of diabetes-associated atherosclerosis, prolonged carnosine supplementation enhances plasma levels, and has novel and significant effects on atherosclerotic lesion lipid, collagen and macrophage levels. These data are consistent with greater lesion stability, a key goal in treatment of existing cardiovascular disease. Carnosine supplementation may therefore be of benefit in lowering triglyceride levels and suppressing plaque instability in diabetes-associated atherosclerosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bianchi C.
        • Miccoli R.
        • Daniele G.
        • Penno G.
        • Del Prato S.
        Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.
        Diabetes Care. 2009; 32: S342-S348
        • Hsueh W.A.
        • Abel E.D.
        • Breslow J.L.
        • et al.
        Recipes for creating animal models of diabetic cardiovascular disease.
        Circ Res. 2007; 100: 1415-1427
        • Jandeleit-Dahm K.
        • Cooper M.E.
        The role of AGEs in cardiovascular disease.
        Curr Pharm Des. 2008; 14: 979-986
        • Boldyrev A.A.
        • Aldini G.
        • Derave W.
        Physiology and pathophysiology of carnosine.
        Physiol Rev. 2013; 93: 1803-1845
        • Hipkiss A.R.
        Carnosine and its possible roles in nutrition and health.
        Adv Food Nutr Res. 2009; 57: 87-154
        • Barski O.A.
        • Xie Z.
        • Baba S.P.
        • et al.
        Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice.
        Arterioscler Thromb Vasc Biol. 2013; 33: 1162-1170
        • Rashid I.
        • van Reyk D.M.
        • Davies M.J.
        Carnosine and its constituents inhibit glycation of low-density lipoproteins that promote foam cell formation in vitro.
        FEBS Lett. 2007; 581: 1067-1070
        • Menini S.
        • Iacobini C.
        • Ricci C.
        • et al.
        D-carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation.
        Br J Pharmacol. 2012; 166: 1344-1356
        • Mong M.-C.
        • Chao C.-Y.
        • Yin M.-C.
        Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet.
        Eur J Pharmacol. 2011; 653: 82-88
        • Stvolinsky S.L.
        • Bulygina E.R.
        • Fedorova T.N.
        • et al.
        Biological activity of novel synthetic derivatives of carnosine.
        Cell Mol Neurobiol. 2010; 30: 395-404
        • Aldini G.
        • Orioli M.
        • Rossoni G.
        • et al.
        The carbonyl scavenger carnosine ameliorates dyslipidemia and renal function in zucker obese rats.
        J Cell Mol Med. 2011; 15: 1339-1356
        • Lee Y.-T.
        • Hsi C.-C.
        • Lin M.-H.
        • Liu K.-S.
        • Yin M.-C.
        Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation.
        Eur J Pharmacol. 2005; 513: 145-150
        • Candido R.
        • Jandeleit-Dahm K.A.
        • Cao Z.
        • et al.
        Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
        Circulation. 2002; 106: 246-253
        • McRobb L.
        • Handelsman D.J.
        • Heather A.K.
        Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels.
        Endocrinology. 2009; 150: 841-848
        • Pattison D.I.
        • Hawkins C.L.
        • Davies M.J.
        Hypochlorous acid-mediated protein oxidation: how important are chloramine transfer reactions and protein tertiary structure?.
        Biochemistry. 2007; 46: 9853-9864
        • Ali Z.A.
        • Bursill C.A.
        • Hu Y.
        • et al.
        Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice.
        Circulation. 2005; 112: I-235-I-241
        • Park L.
        • Raman K.G.
        • Lee K.J.
        • et al.
        Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
        Nat Med. 1998; 4: 1025-1031
        • Candido R.
        • Allen T.J.
        • Lassila M.
        • et al.
        Irbesartan but not amlidipine suppresses diabetes-associated atherosclerosis.
        Circulation. 2004; 109: 1536-1542
        • Nestel P.
        • Fujii A.
        • Allen T.
        The cis-9,trans-11 isomer of conjugated linoleic acid (CLA) lowers plasma triglyceride and raises HDL cholesterol concentrations but does not suppress aortic atherosclerosis in diabetic apoE-deficient mice.
        Atherosclerosis. 2006; 189: 282-287
        • Yamano T.
        • Niijima A.
        • Iimori S.
        • Tsuruoka N.
        • Kiso Y.
        • Nagai K.
        Effect of l-carnosine on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats.
        Neurosci Lett. 2001; 313: 78-82
        • Levi Z.
        • Shaish A.
        • Yacov N.
        • et al.
        Rosiglitazone (PPAR-γ-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
        Diabetes Obes Metab. 2003; 5: 45-50
        • Small D.M.
        • Shipley G.G.
        Physical–chemical basis of lipid deposition in atherosclerosis.
        Science. 1974; 185: 222-229
        • Libby P.
        Inflammation in atherosclerosis.
        Nature. 2002; 420: 868
        • Reimers G.J.
        • Jackson C.L.
        • Rickards J.
        • et al.
        Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I.
        Cardiovasc Res. 2011; 91: 37-44
        • Davies M.J.
        The oxidative environment and protein damage.
        Biochim Biophys Acta. 2005; 1703: 93-109
        • Gebicki S.
        • Bartosz B.
        • Gebicki J.M.
        Peroxidation of proteins by free radicals and its consequences to living organisms.
        Curr Topics Biophys. 1995; 1995: 220-226
        • Lo T.W.C.
        • Selwood T.
        • Thornalley P.J.
        The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins.
        Biochem Pharmacol. 1994; 48: 1865-1870
        • Requena J.R.
        • Fu M.-X.
        • Ahmed M.U.
        • et al.
        Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidised human low-density lipoprotein.
        Biochem J. 1997; 322: 317-325
        • Hoff H.F.
        • O'Neil J.
        • Chisolm G.D.
        • et al.
        Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages.
        Arteriosclerosis. 1989; 9: 538-549
        • Ishii T.
        • Itoh K.
        • Ruiz E.
        • et al.
        Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal.
        Circ Res. 2004; 94: 609-616